Remember last year when Allergan thought of a really creative way to hold on to their Restasis patents?
If not, here is your 30 second recap.
In September of last year, Allergan transferred their Restasis patents to a Native American Tribe. Because Allergan is facing several patent challenges (Mylan being the big one), their hope was that the Tribe could claim sovereign immunity which could then dismiss these challenges.
Did it work?
No. A judge recently denied the request from the Tribe to terminate Mylan’s patent challenge. Which means the showdown is on for a generic version of Restasis.
When do the Restasis patents expire?
August 27, 2024.